(Q83226453)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243448%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243448%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

0 references

1

Bo Ahrén

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243448%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243448%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

published in

Current diabetes report

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243448%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243448%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243448%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

83-90

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243448%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11892-011-0179-x

20 January 2020

exact match

0 references

cites work

Alpha cell function in health and disease: influence of glucagon-like peptide-1.

1 reference

12 December 2020

Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide

1 reference

12 December 2020

Sitagliptin: a review of its use in the management of type 2 diabetes mellitus

1 reference

12 December 2020

Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care.

1 reference

12 December 2020

Localization of sulfonylurea receptor subunits, SUR2A and SUR2B, in rat heart

1 reference

12 December 2020

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors

1 reference

12 December 2020

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

1 reference

12 December 2020

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

1 reference

12 December 2020

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

1 reference

12 December 2020

The role of sulphonylureas in the management of type 2 diabetes mellitus

1 reference

12 December 2020

Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes

1 reference

12 December 2020

Comparison of efficacy, secondary failure rate, and complications of sulfonylureas

1 reference

12 December 2020

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.

1 reference

12 December 2020

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

12 December 2020

Sulphonylurea action revisited: the post-cloning era.

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

1 reference

12 December 2020

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

1 reference

12 December 2020

Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences.

1 reference

12 December 2020

Effects of intensive glucose lowering in type 2 diabetes

1 reference

12 December 2020

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

12 December 2020

A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results

1 reference

12 December 2020

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

1 reference

12 December 2020

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

12 December 2020

Hypoglycaemia in Type 2 diabetes

1 reference

12 December 2020

Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?

1 reference

12 December 2020

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

1 reference

12 December 2020

The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence

1 reference

12 December 2020

Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties

1 reference

12 December 2020

The role of GLP-1 in the life and death of pancreatic beta cells.

1 reference

12 December 2020

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

1 reference

12 December 2020

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

1 reference

12 December 2020

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

12 December 2020

Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets

1 reference

12 December 2020

Characterisation of sulphonylurea and ATP-regulated K+ channels in rat pancreatic A-cells

1 reference

12 December 2020

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

1 reference

12 December 2020

Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

1 reference

12 December 2020

Sulfonylureas: background and development of the field

1 reference

12 December 2020

Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance.

1 reference

12 December 2020

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

1 reference

12 December 2020

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

12 December 2020

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

1 reference

12 December 2020

The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency

1 reference

12 December 2020

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy

1 reference

12 December 2020

Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.

1 reference

12 December 2020

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

1 reference

12 December 2020

Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women

1 reference

12 December 2020